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Abstract 
Ketotifen fumerate ophthalmic solution is an antihistaminic drug.  The 
aim of this study was to develop a novel aqueous ketotifen eye drop 
formulation containin ketotifen/2-Hydroxypropyl-β-cyclodextrin 
complex, which has the ability to enhance the solubility of the drug at the 
physiological pH (7.4), consequently decreasing the irritation to the eye. 
Moreover, increaseing the fraction of the unionized drug leads to 
enhancing the permeability of the drug through the cornea. The stability 
constant was determined from phase-solubility diagrams and found to be 
higher with KF/HP-ß-CD complex (29.47 M−1) than KF/ß-CD complex 
(10.36 M−1). Differential scanning calorimetry (DSC),  fourier transform-
infrared (FT-IR) spectroscopy and X-ray analysis (X-ray) showed the 
formation and the physiochemical proporties of the complex. The effect 
of different additives including; antioxidants, isotonicity adjusting agents 
and preservatives on the stability of ketotifen fumerate solution were 
studied.  Sodium ascorbate (0.1%w/v) showed a significant increase in the 
stability of the KF solutoion.  Fluid thioglycolate medium and Tryptic 
Soy Broth were used as a medium to test of sterility of selected 
formulations to detect aerobic, anaerobic and fungal contamination and 
verified that no turbidity or surface growth was observed during the 
incubation period of all tested formulae. Finally, the chemical stability 
using the stability indicating HPLC assay showed that the stability of the 
selected formulation were significantly higher in comparison to that of a 
commercial product (Zaditen® eye drops Novartis Pharma-Egypt) 
(p>0.05). These results indicate that KF/HP-ß-CD eye drops formulation 
is a promising (formulation) resulting in enhancing the solability, stability 
and permeability of the drug.  
Keywords: Ketotifen Fumerate; 2-Hydroxypropyl-ß-cyclodextrin; 
Inclusion complex; Solubility; Stability. 
 
Introduction 
The human eye has always been a challenging 
subject for topical administration of drugs.  Many 
attempts have been made to deliver ophthalmic 
drugs to the eye by means of different drug 
delivery systems [1]. To achieve effective 
ophthalmic therapy, most drugs must penetrate 
through the eye tissue barriers (e.g., cornea, and 
conjunctiva) to reach the therapeutic targets. 
Furthermore, an adequate drug concentration 
must be maintained at the site of action within the 
eye for an extended time up to several hours [2, 
3]. The principle disadvantage of ophthalmic 
solution is the relatively short contact time 
between the drug and absorbing surfaces which 
may be increased to some extent by addition of 
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viscosity inducing agents. Solutions to be applied 
to mucous membrane tissues are liable to cause 
irritation if their pH is greatly (removed) from the  
normal pH of the relevant body fluid optimum as 
patient comfort is usually found at the pH of the 
tear fluid, about 7.4[4]. 
 
Ketotifen is a relatively selective, non-
competitive histamine antagonist (H1-receptor) 
and mast cell stabilizer. Ketotifen inhibits the 
release of mediators from cells involved in 
hypersensitivity reactions [5]. However, its 
commercial preparation (Zaditen® eye drops 
Novartis Pharma-Egypt) has an acidic pH of 4.4 
to 5.6 that affects patient compliance by causing 
irritation to the eye.  
 
Cyclodextrins (CDs) are shown to be nontoxic 
and well tolerated in eye drop formulations. CDs 
are water-soluble complexing agents that are able 
to solubilize poorly soluble drugs, and enhance 
their permeation through biological membranes, 
(through formation of water-soluble 
complexes)[6-8]. In ophthalmic preparations, 
drug/CD complexes have been shown to increase  
the drug permeation through the cornea[8, 9].  
Moreover, the chemical stability of many active 
substances has been improved by (complexation) 
with different cyclodextrins.  
 
The main object of this study is to develop and 
evaluate KF/HP-ß-CD inclusion complex and to 
prepare a novel eye drop solution of KF suitable 
for ophthalmic use. 
  
Materials and methods  
Materials 
Ketotifen fumarate (Wuhan Yuanvheng Co, 
China, generously gifted by Memphis Co., 
Egypt). 2Hydroxy propyl- ß-cyclodextrin and ß-
cyclodextrin (chemical Co., Milwaukee, WI, 
USA).  Polyvinyl alcohol (PVA 1500), sodium 
ascorbate, benzalkonium chloride, methyl 
paraben, propylen glycol (EL-Nasr 
pharmaceutical chemical company, Egypt). 
Triethaylamine, methanol (HPLC grade ,Romil 
chemical, England). Disodium hydrogen 
phosphate, potassium dihydrogen phosphate 
(E.Merck, Darmstadt, Germany). All other 
ingredients were of analytical grade. 
 
Methods 
Saturated solubility study  
The saturated solubilities of KF in distilled water 
and in phosphate buffers of pHs (4.5-7.8) were 
carried out.  An excess amount of the drug was 
shaken with each solution at room temperature 
(25±1ºC) until equilibrium. The solutions were 
then filtered through a Millipore filter (pore size 
0.45 µm, Millipore, Milford, USA.), and the 
concentration was determined 
spectrophotometrically at λmax 300 nm.  
 
Partition coefficient study  
The partition coefficients of KF between  n-
octanol (represents organic phase) while,  distilled 
water and phosphate buffers of pHs ranging from 
4.5-7.8 (represent the aqueous phase) were 
determined according to the McDaid and Deasy 
method [10].  Equal volumes (50 ml) of n-octanol 
and each of the aqueous solutions were mixed and 
shaken for six hours, at (25±1ºC). The two phases 
were left to separate overnight. A known 
concentration of the drug was added and the 
solutions were shaken for 24 hours. The two 
phases were then separated using a separating 
funnel. The separated aqueous phases were 
assayed spectrophotometrically at λmax 300 nm to 
determine their concentrations; consequently, the 
amount partitioned into n-octanol phase was 
calculated. The partition coefficient was 
expressed as the ratio between the drug 
concentration in the n-octanol phase and the drug 
concentration in the aqueous phase (% w/v).  
 
Phase solubility studies  
Excess amounts of ketotifen fumerate were added 
to phosphate buffer solutions containing 
increasing concentrations of the ß-CD and HP-ß-
CD (ranging from 3 to 100 mM) in a series of 
glass stoppered bottles, the pH was adjusted at 
7.4±0.2. run on sentence.  The obtained 
suspensions were shaken at 37±0.5°C for 7 days. 
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Aliquots were withdrawn and the filtered through 
a Millipore filter. The filtered solutions were 
measured spectrophotometrically at λmax 300 nm. 
The stability constants K1:1 were estimated from 
the straight line of the phase solubility diagrams 
[11]  according to equation (1) 
 
    K1:1=slope/So(1-slope)                    ……….(1) 
Where So represents the drug solubility in 
absence of cyclodextrins (the intercept of the 
phase solubility diagram). The complexation 
efficiency (CE)[12] was calculated according to 
equation (2)   
 
 CE=S0K1:1=[drug-CD]/[CD]=slope/1-slope …(2) 
 
Where [drug-CD] is the concentration of the 
drug-CD complex and [CD] is the concentration 
of the free cyclodextrin. 
 
Preparation of solid inclusion complex 
Inclusion complexes were prepared by the 
coprecipitation method [13]. The clear solutions 
of HP-ß-Cyclodextrin in distilled water and KF in 
ethanol-water (80:20, v/v) solution were mixed at 
the molar ratios of (1:1). The obtained solution 
was dried under vacuum at room temperature 
using a rotary evaporator. Further drying of the 
prepared coprecipitate was carried out in a 
dessicator over anhydrous calcium chloride. 
 
Characterization of prepared inclusion 
complex  
Differential scanning calorimetry (DSC) 
DSC studies were performed for pure drug, HP-
ß-CD, the drug- cyclodextrins physical mixture 
(1:1) and the prepared inclusion complex. The 
samples (3-4mg) were placed in aluminum pans 
and the experiments ran in a calorimeter 
(Universal V2.3D TA Instruments) at a 10ºC/min 
heating rate over a  temperature range of 25° to 
300° C.  
 
Fourier transform-infrared (FT-IR) 
spectroscopy 
The FTIR spectra of pure drug, HP-ß-CD, the 
drug- cyclodextrins physical mixture (1:1) and 
the prepared inclusion were recorded using a  
Formulation method 
The weighed quantity of KF/2-HP-ß-CD 
complex, preservatives and antioxidant were 
dissolved in phosphate buffer (pH 7.4). The 
isotonicity was adjusted by addition of sodium 
chloride (0.9% w/v) or propylene glycol (2% 
v/v). The selected formulae were sterilized by 
filtration using 0.22 µm millipore membrane 
filters. Bruker FTIR spectrophotometer according 
to the KBr disc technique. The FTIR 
measurements were performed in the scanning 
range of 4000 - 400 cm-1 at ambient temperature. 
 
X-ray powder diffractometry (X-ray) 
The X-ray diffraction patterns were recorded at 
room temperature using Scintag XGEN-4000 
diffractometer. The samples were irradiated with 
Ni filtered Cu Kα radiation, at a voltage of 45 Kv 
and a current of 40 mA. The scanning rate 
employed was 2°/minute over a diffraction angle 
(2 Ө) range of 3 - 70°. 
 
Table 1.  Factorial design for studying the effect of 
different additives on the eye drops. 
 
*: Represents the different formula number. 
 
Effect of different additives on the stability of 
KF/2- HP-ß-CD complex in eye drops 
formulations  
The effect of different additives including; 
antioxidants, isotonicity adjusting agents and 
preservatives on the stability of ketotifen 
fumerate solution were studied. The experiment 
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was designed according to 23 factorial design, as 
shown in table 1. The results were statistically 
analyzed using one way ANOVA at p<0.05 
(using SPSS® software program). 
The rate constant of decomposition (K) was 
calculated according to the determined order at 
each of the three temperatures. The (K) values at 
different temperatures were plotted against the 
reciprocal of the corresponding temperature on 
logarithmic scale according to the Arrhenius plot 
for the determination of the expiration date[17]  
 
Table  2.  Saturated solubilities of KF in ifferent 
Solutions. 
 
Adjustment of the viscosity of the selected 
formulae 
Saturated Solubility 
(mg/ml) Vehicle 
17.471±2.741 Distilled Water 
94.72±8.462 pH 4.5 Phosphate Buffer 
85.91 ±4.790 pH 5.5 Phosphate Buffer 
62.54±6.024 pH 6  Phosphate Buffer 
11.37±1.273 pH 6.8  Phosphate Buffer 
4.02±0.926 pH 7.4 Phosphate Buffer 
2.91±0.518 pH 7.8  Phosphate Buffer 
Results & Discussion  
Saturated solubility study  
Table 2 shows the saturated solubilities of KF in 
distilled water and in phosphate buffer solutions 
of pHs (4.5-7.8).  The solubility of the drug at 
acidic pH was significantly higher than in water; 
this is due to the alkaline nature of the drug as it 
will be in the ionized form in the acidic medium. 
Upon increasing pH, the unionized species 
predominated, which explain the sharp decrease 
in the solubility at basic pH (7.4 -7.8). 
 
 Partition coefficient study (P) 
Polyvinyl alcohol (0.25% - 3%)[14] was used as 
a viscosity-increasing agent [15]. The different 
concentrations of PVA 1500 were prepared by 
melting them in the selected formulae using 
thermostatically controlled magnetic stirrer at 
70ºC.  
The partition coefficients (P) of KF between n-
octanol and phosphate buffer solutions of pH 
values (4.5-7.8) are shown in table 3. There was 
an increase in (P) upon increasing the pH with a 
sharp rise after a pH of 6.0. This was expected at 
pH values above the pKa of the drug (6.7) where 
the drug will exist mainly in the unionized form.  
Accelerated stability testing  
The sterilized eye drops were aseptically filled in 
volumetric flasks wrapped in aluminum foil and 
stored at 40ºC, 50º C and 60ºC in ovens for 13 
weeks and examined physically for any changes 
and chemically using the HPLC stability 
indicating assay[16]. The HPLC apparatus 
consists of: Isocratic pump LC-10 AS and a 
UV/VIS detector SPD-10A connected to a C-
R6A Integrator (Shimadzu, Koyoto, Japan). The 
analytical column was Ponapak C18 HPLC 
column, 4.6 × 250 I.D mm, particle size 125 ºA 
(Waters Associates, Ireland). The mobile phase 
composed of methanol:water in a ratio of 80:20 
(V/V) containing triethaylamine (0.2%v/v), with 
a flow rate of 1 ml. min-1. The system was 
operated at ambient temperature and the detection 
wavelength was 296 nm.   
Table 3.  Partition coefficient of KF in different tested 
media. 
Partition Coefficient System 
0.676 ±0.0481 Octanol/ Distilled Water 
0.112± 0.062 Octanol/pH 4.5 buffer 
0.131± 0.0658 Octanol/pH 5.5 buffer 
0.263±0.0501 Octanol/Ph 6 buffer 
0.752±0.0801 Octanol/pH 6.8 buffer 
1.601±0.0316 Octanol/pH 7.4 buffer 
1.924±0.0271 Octanol/pH 7.8 buffer 
 
Phase solubility studies 
The phase solubility diagrams of KF with β-CD 
and HP-β-CD in phosphate buffer (pH7.4) at 37 ±   
0.5 °C are graphically illustrated in figure 1 and 
the parameters are shown in table 4.   
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Figure 1.  Phase solubility diagrams of KF with different cyclodextrins in phosphate buffer (pH 7.4) at 37 ± 0.5 ºC. 
 
 
Table  4. Stability constant (K1:1), and the complexation 
efficiency (CE) of KF/cyclodextrins. 
*R2 (determination coefficient)      
  **K1:1 (stability constant) 
 ***CE (complexation efficiency 
 
The solubility of KF increased linearly with the 
addition of HP-β-CD. The correlation coefficient 
value (R2) was equal to 0.9785 indicating the 
formation of Ap type curve[18] . On the other 
hand, the phase solubility diagrams of  KF with 
ß-CD exhibited BS type[19]. The diagram began 
with an initial rising part followed by a plateau 
region. The observed decrease in the amount of 
KF dissolved could be attributed to the 
precipitation of microcrystalline complex at  
higher cyclodextrin concentration. The 
complexation efficiency (CE) was calculated 
form equation (2). Since the value of the 
complexation efficiency (CE) is dependent only 
on the slope of the phase solubility profile, less 
variation is usually observed in CE values 
compared to K 1:1 value which contains So of the 
drug. The CE values were computed and found to 
be 0.09685 and 0.28866 for KF/β-CD and 
KF/HP-β-CD respectively. Therefore KF had 
higher affinity for HP-β-CD and, thus, was 
selected for further investigation. The high 
affinity to HP-β-CD might be due to the 
hydrophilicity of HP-ßCD, which gave good 
adjustment of ketotifen fumarate to the 
cyclodextrin cavity. 
 
KF/cyclodextrins  
Characterization of prepared inclusion 
complex  
Differential scanning calorimetry (DSC) 
Figure 2.  Shows the DSC thermograms of pure 
KF, (KF/ HP-ßCD), 1:1 physical mixtures and 
the inclusion complex. It was clear that the sharp 
endothermic peak of the drug, around 200ºC, 
became shorter in the thermograph of the 
physical mixtures which may be attributed to the 
reduced purity of samples after mixing[20].   
Inclusion complex of  KF with  
cyclodextrins Parameter  
Β-CD HP- β-CD 
Complexation 
medium 
phosphate buffer  
pH (7.4) 
Phosphate  
buffer 
pH (7.4) 
Curve Type BS Ap 
S0 (M)   9.344 x 10-3 9.4626 x 10-3 
Slope 0.0883 0.224 
R2* 0.9128 0.9785 
K1:1** 10.364 29.474 
CE***  0.09685 0.28866 
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 For HP-ß-CD, it was also observed that a peak 
around 60ºC corresponds to water loss. On the 
other hand, the characteristic peak of the drug 
totally disappeared in the complexes 
thermograph. This result proved formation of 
inclusion complex characteristic to cyclodextrins. 
A similar effect was reported by Liu and Zhu [21] 
for inclusion complexes of prazosin 
hydrochloride with HP-β-CD. 
Figure 2.  DSC thermograms of KF-H-β-cyclodextrin 
solid systems..  (a) Pure Ketotifen fumerate; (b) Pure 
HP-β-CD; (c) Physical mixture and (d) Coprecipitation. 
 
Fourier-transform infrared spectroscopy 
FTIR spectroscopy was used to confirm the 
interaction between KF and HP-ß-CD as changes 
or shifts in the drug’s absorption spectrum occur 
upon complexation[22]. The IR spectra are 
illustrated in figure 2. KF shows its characteristic 
peaks at 3097.1 cm-1 assigned to –CH thiophene 
stretching, 3000-2840 cm-1 assigned to aromatic 
stretching, 1650 cm-1 for carbonyl group, while, 
the spectra of HP-ß-CD illustrate an intense broad 
absorption bands at 3500-3300 cm-1 
corresponding to the free –OH stretching 
vibration [23]. 
 
 
 
 
 
Figure 3. FTIR patterns of KF-H-β-cyclodextrin solid systems.  (a) Pure Ketotifen fumerate; (b) Pure HP-β-CD; (c) 
Physical mixture and (d) Coprecipitation. 
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The spectra of the physical mixtures were the 
superposition of pure components spectra, 
indicating the absence of interaction between KF 
and HP-ßCD in the physical mixture. This result 
was in agreement with the work of Fernandes et 
al [24]. The IR spectra of (KF/ HP-ßCD) complex 
corresponding to thiophene was strongly 
stretched, explained by the dissociation of the 
intermolecular hydrogen bonds associated with 
crystalline drug molecules. The broadening and 
the decrease in the intensity of the drug’s 
aromatic stretching band observable in these 
systems might be due to its restriction within the 
cyclodextrin cavity [25].  
 
 
Figure 4. X-ray diffraction patterns of KF-H-β-cyclodextrin solid systems. (a) Pure Ketotifen fumerate; (b) Pure HP-β-
CD; (c) Physical mixture and(d) Coprecipitation. 
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Figure 5. Viscosity of the prepared eye drops (F3 and F7) containing different concentrations of PVA 1500. 
 
X-ray powder diffractometry studies 
X-ray diffractograms confirmed the crystalline 
nature of KF, while HP-ß-CD was presented as 
an amorphous structure. The diffractogram of the 
physical mixture could be considered the 
superposition of the patterns of the pure 
components with some variations in the shapes 
and intensities of the characteristic diffraction 
peaks, (shown in figure 5) while the inclusion 
complex showed that the crystalline KF pattern 
disappeared. However, lower intensities of the 
diffraction peaks were observed due to particle 
size reduction during mixing and dilution of the 
pure crystalline components. These results are in 
strong agreement with the work of Bayomi et al. 
[26] who studied the inclusion complexation of 
nifedipine with cyclodextrins using the 
coprecipitation method.  
 
Stability of the different Formulations  
Eight formulations of eye drops were 
investigated. Table 5 shows the percent of KF 
remaining after different time intervals.  
Statistical analysis was preformed to detect the 
significant differences between the different 
additives. The results showed the stability of the 
eye drop formulations (F3, F4, F7 and F8) which 
contained sodium ascorbate (0.1%w/v) were 
significantly higher than the formulations (F1, 
F2, F5 and F6) which contained sodium ascorbate 
(0.05%w/v)    The other different types of 
isotonicity adjusting agents and preservatives 
showed no significant difference (p>0.05) with 
the stability of the eye drops. From these results 
F3 and F7 were chosen for further tests, due to 
their greatest stability. 
 
Adjustment of the viscosity of the selected 
formulae 
Figure 5 shows that PVA 1500 in concentration 
of 1.5% (w/v) was found to have a suitable 
viscosity with F5 (5.23 cP)[27], while PVA 1500 
in concentration of 1.00% (w/v) exhibited a 
suitable viscosity of all the tested solutions of F7 
 (5.49cP). 
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Table 5. Stability of different eye formulae during the storage at 60°C for 45 days.  
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Figure 6. Chemical stability of KF in the tested eye drops of F3. 
 
Sterility testing of the selected eye drops 
formulations 
Sterility testing of the prepared eye drops was 
performed according to the procedure described 
by USP[28]. Fluid thioglycolate medium was 
used to detect both aerobic and anaerobic 
bacterial contaminants, while Tryptic Soy Broth 
was used to detect both bacterial and fungal 
contamination.  All the samples tested passed the 
sterility test, where no turbidity or surface growth 
was observed during the incubation period of all 
tested samples. 
 
Physical stability 
None of the selected formula solutions stored at 
the three elevated temperatures for three months 
Percent of KF remaining after storage at 60°C for the following time intervals (in days)Formula 
no. 0 2 7 14 21 28 36 45 
F1 100.4±0.52 99.12 ±1.02 
98.33 
±1.25 
96.63 
±0.94 
94.95 
±0.72 
93.24 
±1.05 
92.51 
±0.69 
91.42 
±0.893 
F2 99.73±0.40 97.69 ±0.59 
96.21 
±0.47 
93.04 
±0.69 
91.62 
±0.89 
89.39 
±0.74 
87.18 
±0.72 
84.96 
±0.685 
F3 99.64±0.89 99.37 ±0.74 
99.05 
0.592 
98.75 
±0.92 
98.18 
±0.46 
97.26 
±0.61 
96.02 
0.980 
95.35 
±0.148 
F4 99.52±0.81 96.72 ±1.35 
95.3 
±1.50 
94.27 
±0.95 
92.19 
±0.82 
91.05 90.49 
±1.16 ±0.79 
88.92 
0.991± 
F5 100.1±0.87 99.03 ±1.12 
97.75 
±1.0 
96.46 
±0.95 
95.87 
±1.24 
94.02 
±1.19 
93.30 
±0.85 
89.83 
±0.926 
F6 99.18±0.58 98.78 ±0.73 
97.77 
±0.91 
95.81 
±0.96 
92.06 
±1.14 
90.36 
±1.08 
88.90 
±1.37 
86.94 
±0.981 
F7 100.0±0.47 100.1 ±0.85 
99.91 
±0.91 
99.86 
±1.11 
99.75 
±0.87 
99.42 
±0.92 
98.87 
±0.71 
98.17 
±0.126 
F8 99.68±0.38 97.01 ±0.69 
96.78 
±0.91 
94.13 
±1.06 
93.24 
±0.72 
92.55 
±0.96 
91.18 
±1.26 
90.08 
±1.380 
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showed any change in color, appearance or 
clarity throughout the storage period. 
 
Chemical stability 
The selected formulae F3 and F7 were subjected 
to accelerated stability study to clarify the 
expiration date of the formula under normal 
storage conditions in comparison with the 
commercially available Zaditen® eye drops. The 
results of the accelerated stability testing of the 
drug in the prepared eye drops were presented in 
figure 7, 8 and 9. All the tested formulae were 
within the range permitted by the USP (90-
120%). 
 
Kinetic analysis of the stability data reveals that 
KF degradation followed first-order kinetics. The 
K values (decomposition rate constant) of the 
prepared formula at different temperatures were 
plotted graphically on a logarithmic scale, as 
illustrated in figure 9.  
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Figure7. Chemical stability of KF in the tested eye drops of F7. 
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Figure  8. Chemical stability of KF in the tested eye drops of Zaditen® eye drops. 
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Figure 9. A Plot of K Values of KF eye drops formulations F3, F7 and the commercial available Zaditen® after three 
months of storage on logarithmic scale. 
 
 
 
The predictive shelf life was calculated [4],  
according to the equation (3).   
  
 t 90 = 0.105 / K 25            (3) 
 
Where t 90 is the time at which the percent drug 
remained is 90%. The tested formula F3, F7 and 
Zaditor eye drops possessed a predictive shelf life 
of 2.89, 2.52 and 1.85 years respectively, as 
shown in table 6. 
 
 
Table 6.  Kinetic data of accelerated stability testing of KF prepared eye drops 
 
 
 
 
K Values at the Following Temperatures 
(ºK) on Logarithmic Scale  
Formula 
no.  
313 °K 
 
323 °K 333 °K 
 
K25 
(weeks-1) 
 
t ½ 
at 25°C 
(years) 
 
t 90 
at 25°C 
(years) 
F3 0.00161 0.00207 0.00276 0.00070 19.038 2.885 
F7 0.0016 0.00207 0.00253 0.00082 16.659 2.524 
Zaditen® 
E.D 0.0021 0.0028 0.0034 0.00108 12.339 1.8457 
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Conclusions 
This study demonstrated that the inclusion 
complex of KF-HP-ßCD in eye drop preparations 
is a promising formulation resulting in enhancing 
the solubility, permeability and stability of KF 
eye drops prepared at the physiological pH.  
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